TFW



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

AMENDMENT TRANSMITTAL LETTER		Docket Number: 1662/607041	
Application Number 10/759,906	Filing Date January 16, 2004	Examiner Rita J. Desai	Art Unit 1625
Invention Title Novel Synthesis of Irbesartan		Inventors NISNEVICH, et al.	

Commissioner for Patents P.O. Box 1450 Alexandra, VA 22313-1450 I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 3/21/05

Signature: Ages

Agnes XV

Sir:

Transmitted herewith for filing is a response to the Restriction Requirement mailed February 22, 2005, for the above-identified application. A response to which is due on March 22, 2005.

No additional fee is believed to be due. However, if any fees are due the Commissioner is authorized to charge deposit account No. 11-0600 for such fees. A duplicate copy of this letter is enclosed for that purpose.

Date: 3/21/05

Respectfully submitted,

John B. Starr, Jr.

Reg. No. 44,474

KENYON & KENYON

One Broadway

New York, New York 10004

(212) 425-7200 (telephone)

(212) 425-5288 (facsimile)

CUSTOMER NUMBER 26646



PATENT Ser. No. 10/759,906 Atty. Docket No. 1662/607041

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: NISNEVICH, et al.

Art Unit:

1625

Serial No.:

10/759,906

Examiner:

Rita J. Desai

Filed:

January 16, 2004

For:

Novel Synthesis of Irbesartan

Docket No.:

1662/607041

Address to: Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with sufficient postage with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Signature:

Agnes Xu

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

In response to the communication from the Office mailed February 22, 2005, applicants hereby elect, without traverse, the claims of Group VII (ie. claims 33-35) for examination in the present application. Applicants expressly reserve the right to prosecute the subject matter of the non-elected claims in one or more continuation or divisional applications.

If, in the opinion of the Examiner, a telephone conference would advance the prosecution of the Application, the Examiner is invited to telephone the undersigned attorney.

Dated: (3/21/05

John B. Starr, Jr.

(Reg. No. 44,474)

KENYON & KENYON

One Broadway

New York, New York 10004

(212) 908-6257 (Telephone-direct)

(212) 425-5288 (Fax)

CUSTOMER NUMBER 26646